Neuroendocrine neoplasms (NENs) are heterogeneous tumors with a common phenotype. There are two fundamentally different groups of NENs: well-differentiated, low-proliferating NENs, called neuroendocrine tumors (NETs) or carcinoids, and poorly differentiated, highly proliferating NENs, called small- or large-cell neuroendocrine carcinomas (NECs). This NEN dichotomy is probably due to an origin from different neuroendocrine progenitor cells. The current World Health Organization (WHO) classification of gastrointestinal NENs uses the Ki67 proliferation index to grade NETs as G1 or G2, and NECs as G3. In the pancreas, NETs and NECs may overlap in their proliferation index, making the distinction between them difficult and leading to therapeutic uncertainties. Therefore, the WHO classification of pancreatic NENs (PanNENs) from 2017 introduced a new NET G3 category. Helpful for the distinction of NETs G3 from NECs is the expression of p53 and rb1 that is usually negative in PanNETs. Comparison of the WHO classification of digestive system NENs with other NEN classifications reveals site-specific differences in terminology and a general lack of grading systems. However, all classifications recognize the existence of the two major NEN families and provide a general basis for their prognostic and therapeutic stratification. A development of a common NEN classification across organs is desirable.

Keywords:
Neuroendocrine neoplasms, Heterogeneity, Origin, Classification, Gut, Pancreas
1.
Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM: The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011;396:273-298.
2.
Gosset A, Masson P: Tumeurs endocrines de l'appendice. Presse Med 1914;25:237-240.
3.
Feyrter F: Über diffuse endokrine epitheliale Organe. Leipzig, J.A. Barth, 1938.
4.
Modlin IM, Champaneria MC, Bornschein J, Kidd M: Evolution of the diffuse neuroendocrine system - clear cells and cloudy origins. Neuroendocrinology 2006;84:69-82.
5.
Pearse AG: The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17:303-313.
6.
Rosai J: The origin of neuroendocrine tumors and the neural crest saga. Mod Pathol 2011;24(suppl 2):S53-57.
7.
Rindi G, Wiedenmann B: Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2011;8:54-64.
8.
Pavel ME, Singh S, Strosberg JR, et al: Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; DOI: 10.1016/S1470-2045(17)30471-0.
9.
Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G: Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-560.
10.
Solcia E, Klöppel G, Sobin L: Histological Typing of Endocrine Tumours, ed 2. Springer, Berlin, 2000.
11.
DeLellis RA, Lloyd RV, Heitz PU, Eng C: Pathology and genetics of tumours of endocrine organs, ed 3. Lyon, IARC Press, 2004.
12.
Rindi G, Klöppel G, Ahlman H, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
13.
Rindi G, Klöppel G, Couvelard A, et al: TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-762.
14.
Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System, ed 4. Vol. 3. Lyon, IARC Press, 2010.
15.
Lloyd RV, Osamura RY, Klöppel G, Rosai J: WHO Classification of Tumours of Endocrine Organs. Lyon, IARC Press, 2017.
16.
Rindi G, Arnold R, Bosman F, et al: Nomenclature and classification of neuroendocrine neoplasms of the digestive system; in Bosman F, Carneiro F, Hruban R, Theise N (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC Press, 2010, pp 13-14.
17.
Klimstra DS: Pathologic Classification of neuroendocrine neoplasms. Hematol Oncol Clin North Am 2016;30:1-19.
18.
Volante M, Brizzi MP, Faggiano A, et al: Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20:1172-1182.
19.
Konukiewitz B, Schlitter AM, Jesinghaus M, et al: Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol 2017;30:587-598.
20.
Anlauf M, Schlenger R, Perren A, et al: Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006;30:560-574.
21.
Perigny M, Hammel P, Corcos O, et al: Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol 2009;33:739-748.
22.
Jiao Y, Shi C, Edil BH, et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-1203.
23.
Yachida S, Vakiani E, White CM, et al: Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012;36:173-184.
24.
Scarpa A, Chang DK, Nones K, et al: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 2017;543:65-71.
25.
Marinoni I, Kurrer AS, Vassella E, et al: Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 2014;146:453-460.e5.
26.
Schmitt AM, Marinoni I, Blank A, Perren A: New genetics and genomic data on pancreatic neuroendocrine tumors: implications for diagnosis, treatment, and targeted therapies. Endocr Pathol 2016;27:200-204.
27.
Agaimy A, Erlenbach-Wunsch K, Konukiewitz B, et al: ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol 2013;26:995-1003.
28.
Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC: Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014;120:2814-2823.
29.
Heetfeld M, Chougnet CN, Olsen IH, et al: Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015;22:657-664.
30.
Hijioka S, Hosoda W, Matsuo K, et al: Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res 2017;23:4625-4632.
31.
Swarts DR, Ramaekers FC, Speel EJ: Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 2012;1826:255-271.
32.
Schonhoff SE, Giel-Moloney M, Leiter AB: Minireview: development and differentiation of gut endocrine cells. Endocrinology 2004;145:2639-2644.
33.
van Eeden S, Offerhaus GJ: Historical, current and future perspectives on gastrointestinal and pancreatic endocrine tumors. Virchows Arch 2006;448:1-6.
34.
Hermann G, Konukiewitz B, Schmitt A, Perren A, Klöppel G: Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch 2011;459:147-154.
35.
Anlauf M, Perren A, Henopp T, et al: Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut 2007;56:637-644.
36.
Anlauf M, Perren A, Klöppel G: Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 2007;74:279-284.
37.
Perren A, Anlauf M, Henopp T, et al: Multiple endocrine neoplasia type 1: loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters, but not in islet hyperplasia of the pancreas. A combined FISH and immunofluorescence study. J Clin Endocrinol Metab 2007;92:1118-1128.
38.
Pipeleers-Marichal M, Somers G, Willems G, et al: Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990;322:723-727.
39.
Klöppel G, Anlauf M, Perren A, Sipos B: Hyperplasia to neoplasia sequence of duodenal and pancreatic neuroendocrine diseases and pseudohyperplasia of the PP-cells in the pancreas. Endocr Pathol 2014;25:181-185.
40.
Nieser M, Henopp T, Brix J, et al: Loss of chromosome 18 in neuroendocrine tumors of the small intestine: the enigma remains. Neuroendocrinology 2017;104:302-312.
41.
Rindi G, Falconi M, Klersy C, et al: TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012;104:764-777.
© 2017 S. Karger GmbH, Freiburg
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.